Drug intelligence / Profile preview

ERI-0206

Development stage: Preclinical
Lead developer: Factor Bioscience
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

ERI-0206 is a preclinical-stage chimeric antigen receptor (CAR) T-cell therapy developed by Novatium in collaboration with Factor Bioscience. This therapy is engineered to dual-target the CD5 and CD52 antigens, which are associated with renal cell carcinoma (RCC). The dual-targeting strategy is intended to enhance the specificity and potency of the T-cell response against solid tumors, potentially reducing the risk of antigen escape. The program utilizes Factor Bioscience's cell-engineering technologies to create a targeted immunotherapy for patients with renal cell carcinoma.

Other names: Novatium CD5-CD52 CAR-T cell therapy

Targets

CD52 (CD52 Antigen)CD5 (T-cell surface glycoprotein CD5)

Beyond the preview

Go deeper on ERI-0206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ERI-0206.

Explore the full profile